Viking’s new dual GLP-1R/GIPR agonist expected to start Phase III trials soon
American biopharmaceutical company Viking Therapeutics is actively developing several candidates aimed at treating metabolic disorders. Among these is VK2735, a…
American biopharmaceutical company Viking Therapeutics is actively developing several candidates aimed at treating metabolic disorders. Among these is VK2735, a…
Non-Hodgkin’s lymphoma (NHL) is a type of cancer that originates in the lymphatic system, part of the body's immune system.…
Paratek Pharmaceuticals has announced positive topline efficacy and safety data from a global, Phase III, post-marketing commitment study of its…
NewAmsterdam Pharma has completed the enrolment of 407 patients in the pivotal Phase III TANDEM clinical trial evaluating obicetrapib in…
Type 2 diabetes (T2D) is a chronic disorder that results from the body’s inability to make use of available insulin…
Multiple myeloma is the third most common blood malignancy globally. It accounts for 2% of all diagnoses and 1% of…
The US Centers for Disease Control and Prevention (CDC) Health Alert Network issued an advisory on 25 June, regarding an…
BioCity Biopharma recently announced positive results from the ongoing 2-SUCCEED trial. The use of SC0062 resulted in clinically meaningful and…
Genetic, environmental and behavioural risk factors are associated with dementia. But the Lancet Commission on Dementia Prevention, Intervention and Care…
In the US, the disease burden of type 2 diabetes is marked by stark racial inequities. Extensive literature has noted…